Prucalopride

• Description :

  Prucalopride is an orally active, selective and specific 5-HT 4 receptor agonist (high affinity), with pKis of 8.6 and 8.1 for human 5-HT4a/4b receptors, respectively. Prucalopride improves intestinal motility by promoting regeneration of the intestinal nervous system in rats. Prucalopride also shows anticancer activity by blocking of the PI3K/AKT/mTor signaling pathway. Prucalopride can be used in studies of chronic constipation, pseudo-intestinal obstruction and cancer[1][2][3].

• UNSPSC :

  12352005

• Hazard Statement :

  H315, H319, H335, H372, H400

• Target :

  5-HT Receptor; Apoptosis; Autophagy

• Type :

  Reference compound

• Related Pathways :

  Apoptosis; Autophagy; GPCR/G Protein; Neuronal Signaling

• Applications :

  Neuroscience-Neuromodulation

• Field of Research :

  Neurological Disease; Cancer

• Assay Protocol :

  https://www.medchemexpress.com/Prucalopride.html

• Purity :

  99.93

• Solubility :

  DMSO : 100 mg/mL (ultrasonic) |H2O : 50 mg/mL (ultrasonic)

• Smiles :

  ClC1=C(N)C(CCO2)=C2C(C(NC3CCN(CCCOC)CC3)=O)=C1

• Molecular Formula :

  C18H26ClN3O3

• Molecular Weight :

  367.87

• Precautions :

  H315, H319, H335, H372, H400

• References & Citations :

  [1]Chen M, et al. Prucalopride inhibits lung cancer cell proliferation, invasion, and migration through blocking of the PI3K/AKT/mTor signaling pathway. Hum Exp Toxicol. 2020 Feb;39 (2) :173-181. |[2]Wang Y, et al. Prucalopride might improve intestinal motility by promoting the regeneration of the enteric nervous system in diabetic rats. Int J Mol Med. 2022 Jul;50 (1) :87. |[3]Briejer MR, et al. The in vitro pharmacological profile of prucalopride, a novel enterokinetic compound. Eur J Pharmacol. 2001 Jun 29;423 (1) :71-83.

• Shipping Conditions :

  Room Temperature

• Storage Conditions :

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category :

  Reference compound1

• Clinical Information :

  Launched

• Isoform :

  Apolipoprotein D

• CAS Number :

  [179474-81-8]